AlphaGrep UK
CLDX icon

AlphaGrep UK’s Celldex Therapeutics CLDX Stock Holding History

AlphaGrep UK’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$367K Buy
+11,324
New +$433K 0.11% 393

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

AlphaGrep UK's CLDX Position: Q3 2026 in Review

AlphaGrep UK opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 11,324 shares worth $367K. The stake represents 0.11% of the portfolio and ranks #393 among its holdings.

166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • AlphaGrep UK held 11,324 shares of Celldex Therapeutics worth $367K as of Q3 2026.
  • Celldex Therapeutics was a new AlphaGrep UK position in Q3 2026.
  • Celldex Therapeutics made up 0.11% of AlphaGrep UK's portfolio in Q3 2026, its #393 holding.
  • 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.